{"filing":{"accession_number":"0001193125-26-407555","cik":"0001907108","ticker":"LXEO","company_name":"Lexeo Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-29","report_date":"2026-09-29","primary_document":"lxeo-20260929.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1907108/000119312526407555/lxeo-20260929.htm"},"events":[{"id":35769,"run_id":32966,"accession_number":"0001193125-26-407555","anchor_item_number":"2.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"Lexeo Therapeutics completed its acquisition of Mantle for upfront consideration of $5.3 million in cash and $3 million in Lexeo common stock, with contingent milestone payments up to $12 million over 12 years.","company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","filing_date":"2026-09-29","form":"8-K","submitted_at":null,"items":[{"id":39942,"accession_number":"0001193125-26-407555","item_number":"2.01","item_title":"Completion of Acquisition or Disposal of Assets.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"This disclosure describes the completion of a merger in which Lexeo Therapeutics acquired Mantle, with upfront consideration of $5.3 million in cash and $3 million in Lexeo common stock, plus contingent milestone payments up to $12 million over 12 years. The Item 2.01 caption and detailed description of the transaction structure, consideration, and vesting treatment of Mantle securities are unmistakable indicators of a material acquisition completion.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T20:21:39.038940+00:00","company_name":"","ticker":null,"filing_date":""},{"id":39943,"accession_number":"0001193125-26-407555","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses unregistered issuance of Common Stock in connection with a Merger, relying on Section 4(a)(2) and Regulation D exemptions. This is a classic dilutive equity issuance in an M\u0026A context. While the Merger itself is disclosed under Item 2.01, the equity component here represents a material capital event affecting shareholder dilution and is appropriately classified as dilutive_issuance rather than ma_activity, which would focus on the acquisition transaction itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T20:21:39.038940+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39942,"accession_number":"0001193125-26-407555","item_number":"2.01","item_title":"Completion of Acquisition or Disposal of Assets.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"This disclosure describes the completion of a merger in which Lexeo Therapeutics acquired Mantle, with upfront consideration of $5.3 million in cash and $3 million in Lexeo common stock, plus contingent milestone payments up to $12 million over 12 years. The Item 2.01 caption and detailed description of the transaction structure, consideration, and vesting treatment of Mantle securities are unmistakable indicators of a material acquisition completion.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T20:21:39.038940+00:00","company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","filing_date":"2026-09-29"},{"id":39943,"accession_number":"0001193125-26-407555","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses unregistered issuance of Common Stock in connection with a Merger, relying on Section 4(a)(2) and Regulation D exemptions. This is a classic dilutive equity issuance in an M\u0026A context. While the Merger itself is disclosed under Item 2.01, the equity component here represents a material capital event affecting shareholder dilution and is appropriately classified as dilutive_issuance rather than ma_activity, which would focus on the acquisition transaction itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T20:21:39.038940+00:00","company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","filing_date":"2026-09-29"}]}